“Microbiome-friendly” is a front-of-pack claim. It does not identify one ingredient, one preservation strategy, or one agreed definition of a healthy skin microbiome. The International Federation of Societies of Cosmetic Chemists says skin communities vary by person and body site, and that personal- care microbiome terminology is not yet universally standardized (IFSCC guidance).

That means the useful follow-up is: which formula, tested on which skin, with which microbiome method, and what visible or barrier endpoint changed? A pretty bacterial graphic on the carton cannot answer those questions.

What a real study measures

Microbiome studies may collect a swab or tape strip and identify microbial DNA using 16S bacterial or ITS fungal sequencing. IFSCC notes that skin has low microbial biomass, so sampling method, storage, sequencing, and analysis can change what is detected (IFSCC guidance). Finding more DNA is not the same as proving that a microbe is alive, that it changed function, or that the change improved how skin looks or feels.

The cosmetic endpoint matters too. Hydration, transepidermal water loss (TEWL), redness, pH, texture, and participant comfort are different outcomes from “microbiome balance.” A study can report a microbial shift without establishing that the shift is beneficial (IFSCC guidance).

Two human studies worth separating

In a randomized, double-blind split-face study, 14 healthy volunteers aged 23–45 used microbiome-supporting products on one cheek and benchmark products on the other for three weeks. The supporting side showed changes in bacterial reads, species count, diversity, redness, and texture. However, several biophysical changes were not significant against the benchmark, and the authors called for a larger population (Santamaria et al., 2023).

That is a real signal for the tested product set, not a universal result for every product using the phrase “microbiome-friendly.” The study was small, short, and its authors were affiliated with Skinome Research AB, which matters when interpreting a product-category claim (Santamaria et al.).

A second trial randomized 60 women to a control serum or a serum containing galacto-oligosaccharides (GOS), a prebiotic, for eight weeks. The study reported differences in water-holding capacity, TEWL, erythema, selected bacterial populations, and diversity. But only 16 participants were included in the microbiota analysis after exclusions and consent, and the evidence belongs to that GOS formula (Kim et al., 2020; full text).

What “friendly” does not establish

The phrase does not prove that a product:

  • preserves every resident microbe;
  • increases “good” bacteria in a stable, meaningful way;
  • works on every body site or skin type;
  • improves acne, eczema, rosacea, infection, or any other disease; or
  • has the same result when its formula, preservative system, or market version changes.

Those are not endpoints established by the two small cosmetic studies above; the studies instead measured selected microbial and biophysical outcomes (Santamaria et al.; Kim et al.).

Those limits follow from the study designs and from FDA’s broader labeling boundary: cosmetic claims must not be false or misleading, and claims intended to treat or prevent disease can place a product in drug regulation (FDA cosmetics labeling).

Why sampling site matters

The same face can have different microbial communities on the cheek, nose, forehead, and oily versus dry sites. IFSCC describes body site and individual factors as major sources of variation and notes that cosmetics themselves can affect composition (IFSCC guidance). So a study that swabs the alar crease cannot automatically answer a claim about the whole face, and a result from healthy adults cannot automatically answer a claim about irritated skin.

What remains unknown

For a product making this claim, look for the exact formula or tested version, control, participant population, skin site, sampling method, sequencing region, duration, microbial endpoint, barrier/appearance endpoint, and adverse events. The unresolved questions include a universal definition of “friendly,” a clinically useful baseline, fungal effects, persistence after stopping, and whether a measured shift is beneficial rather than merely different.

The verdict is mixed: early controlled studies are worth taking seriously, but “microbiome-friendly” alone is not evidence that a particular bottle will rebalance or protect your microbiome (IFSCC guidance; Santamaria et al.; Kim et al.).

Sources

This answer summarizes cosmetic studies and labeling guidance. It is not medical advice.